Vorolanib is under clinical development by Xcovery Holding Co and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Vorolanib’s likelihood of approval (LoA) and phase transition for Small-Cell Lung Cancer took place on 01 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vorolanib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Vorolanib (X-82) is under development for the treatment of wet age-related macular degeneration, solid tumors including epithelial ovarian adenocarcinoma, metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction, small cell lung cancer, non-small cell lung cancer, thymic carcinoma, renal cell carcinoma, pancreatic neuroendocrine tumors, metastatic renal cell carcinoma, metastatic mucosal melanoma and advanced solid tumors. The drug candidate is administered orally. X-82 is a small molecule indolinone inhibitor of signaling through the growth factor receptors VEGFR and PDGFR.
It was also under development for the treatment of breast cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, fallopian tube cancer, peritoneal cancer, sarcoma and choroidal neovascularization and myopia.
Xcovery Holding Co overview
Xcovery Holding Co (Xcovery Holding) is a biotechnology company. The company is headquartered in United States.
Quick View Vorolanib LOA Data
|Highest Development Stage|